Västra Hamnen Market Focus: Xintela: Moving forward with XSTEM
Idag, 09:15
- Professor Hall comments on the XSTEM study results
- In discussions with investigator-initiated studies
- We keep our fair value of SEl 1.04 per share
Xintela’s year-end report did not reveal any substantial surprises. The recent rights issue and loan facility have given the company temporary financial relief. In February, Xintela announced its clinical study with XSTEM in difficult-to-heal leg ulcers (VLU) was completed, and the final study results are expected by the end of May. In the report, CEO Evy Lundgren-Åkerlund referred to discussions regarding investigator-initiated phase II studies with XSTEM in both VLU and osteoarthritis. If these studies materialise, they could change Xintela’s capital needs and would prompt us to revise our model. As of now, we make only minor adjustments and thus keep the fair value at 1.04 SEK per share.
Read the full report here.
About Market Focus
The research report is prepared as part of Market Focus, Västra Hamnen Corporate Finance's commissioned research offering.
This is a press release from Västra Hamnen Corporate Finance AB.
Web: vhcorp.se
Twitter: @vhcorp_se (https://x.com/vhcorp_se)
Västra Hamnen Market Focus: Xintela: Moving forward with XSTEM
Idag, 09:15
- Professor Hall comments on the XSTEM study results
- In discussions with investigator-initiated studies
- We keep our fair value of SEl 1.04 per share
Xintela’s year-end report did not reveal any substantial surprises. The recent rights issue and loan facility have given the company temporary financial relief. In February, Xintela announced its clinical study with XSTEM in difficult-to-heal leg ulcers (VLU) was completed, and the final study results are expected by the end of May. In the report, CEO Evy Lundgren-Åkerlund referred to discussions regarding investigator-initiated phase II studies with XSTEM in both VLU and osteoarthritis. If these studies materialise, they could change Xintela’s capital needs and would prompt us to revise our model. As of now, we make only minor adjustments and thus keep the fair value at 1.04 SEK per share.
Read the full report here.
About Market Focus
The research report is prepared as part of Market Focus, Västra Hamnen Corporate Finance's commissioned research offering.
This is a press release from Västra Hamnen Corporate Finance AB.
Web: vhcorp.se
Twitter: @vhcorp_se (https://x.com/vhcorp_se)
Börser
Iran
Börser
Mest läst
Iran
Marknadsöversikt
1 DAG %
Senast
1 mån
